Cancer Immunotherapy Breakthrough: A personalized PRAME-targeted T-cell therapy produced a complete response in a 17-year-old with treatment-resistant metastatic nephroblastoma, with no viable tumor cells detected months later and a Phase I/II trial planned for 2027. Long-Term Cancer Care: CD19 CAR T cells (tisagenlecleucel) stayed functionally active for up to a decade in B-cell lymphoma patients, with no relapses beyond 5.4 years in a long follow-up study. Public Health & Housing: A Glasgow mother says worsening damp, mould and vermin in a council flat harmed her son’s health, forcing them to move out while repairs are awaited—an urgent reminder of how housing conditions affect respiratory wellbeing. Lyme Prevention in Europe: EMA is set to study an experimental Lyme vaccine after trial results showed about 70% efficacy in ages 5+; tick seasons may be lengthening as seasons warm. Estonia TB Vaccination Shift: Estonia is considering moving from universal newborn TB vaccination to targeted shots for at-risk children as TB rates decline, with details still being worked out. Mental Health & Metabolic Risk: New genetic findings suggest different links between severe mental disorders and metabolic health—depression aligns more with cardiometabolic pathways, while schizophrenia and bipolar show a reversed pattern. Road Safety (Estonia): Injuries are down but fatalities are up, with speeding behavior still a key concern. Nicotine Policy (Estonia): The economy minister rejected proposed nicotine restrictions for youth, citing insufficient justification and potential impacts on businesses.